Information on the EAMS scientific opinion given to pembrolizumab (MK-3475), including the public assessment report.
PDF, 78.6KB, 3 pages
This file may not be suitable for users of assistive technology.Request a different format.
If you use assistive technology and need a version of this document in a more accessible format, please email webupdates@mhra.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 94.2KB, 5 pages
This file may not be suitable for users of assistive technology.Request a different format.
If you use assistive technology and need a version of this document in a more accessible format, please email webupdates@mhra.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 180KB, 13 pages
This file may not be suitable for users of assistive technology.Request a different format.
If you use assistive technology and need a version of this document in a more accessible format, please email webupdates@mhra.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 80.9KB, 3 pages
This file may not be suitable for users of assistive technology.Request a different format.
This positive scientific opinion was issued to Merck Sharp & Dohme Limited on 9 March 2015 for pembrolizumab, in treatment of advanced melanoma (a type of skin cancer affecting cells called melanocytes), which has spread or cannot be removed by surgery and has progressed after other treatments.
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
Posted on the UK MHRA website on 11 March 2015
